Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Change in Cash (2016 - 2025)

Historic Change in Cash for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$3.7 million.

  • Capricor Therapeutics' Change in Cash fell 10646.71% to -$3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.9 million, marking a year-over-year decrease of 18227.78%. This contributed to the annual value of -$3.4 million for FY2024, which is 16693.08% down from last year.
  • As of Q3 2025, Capricor Therapeutics' Change in Cash stood at -$3.7 million, which was down 10646.71% from -$5.6 million recorded in Q2 2025.
  • Over the past 5 years, Capricor Therapeutics' Change in Cash peaked at $57.7 million during Q3 2024, and registered a low of -$57.1 million during Q4 2024.
  • Its 5-year average for Change in Cash is -$692394.3, with a median of -$768395.0 in 2023.
  • Within the past 5 years, the most significant YoY rise in Capricor Therapeutics' Change in Cash was 686731.26% (2024), while the steepest drop was 109979.87% (2024).
  • Over the past 5 years, Capricor Therapeutics' Change in Cash (Quarter) stood at -$6.0 million in 2021, then skyrocketed by 119.98% to $1.2 million in 2022, then surged by 380.01% to $5.7 million in 2023, then crashed by 1099.8% to -$57.1 million in 2024, then soared by 93.47% to -$3.7 million in 2025.
  • Its Change in Cash was -$3.7 million in Q3 2025, compared to -$5.6 million in Q2 2025 and $17.5 million in Q1 2025.